Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients
- Author
- GOLDSCHMIDT, H1 ; SONNEVELD, P2 ; HOELZER, D6 ; HO, A. D1 ; LOKHORST, H. M7 ; CREMER, F. W1 ; VAN DER HOLT, B3 ; WESTVEER, P3 ; BREITKREUTZ, I1 ; BENNER, A4 ; GLASMACHER, A5 ; SCHMIDT-WOLF, I. G. D5 ; MARTIN, H6
[1] Medizinische Klinik und Poliklinik V, Universität Heidelberg, Hospitalstrasse 3, 69115 Heidelberg, Germany
[2] Department of Hematology, University Hospital Rotterdam, Molewaterplein 40, 3015 GD Rotterdam, Netherlands
[3] Data center, University Hospital Rotterdam, Molewaterplein 40, 3015 GD Rotterdam, Netherlands
[4] Zentraleinheit Biostatistik, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
[5] Medizinische Universitätsklinik und Poliklinik I, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany
[6] Medizinische Klinik III, Universitätsklinik Frankfurt, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany
[7] Department of Hematology, University Hospital Utrecht, Heidelberglaan 100, 3584 CX Utrecht, Netherlands - Source
Annals of hematology (Print). 2003, Vol 82, Num 10, pp 654-659, 6 p ; ref : 34 ref
- ISSN
- 0939-5555
- Scientific domain
- Hematology
- Publisher
- Springer, Berlin
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Keyword (fr)
- Association médicamenteuse Chimiothérapie Dose forte Essai clinique phase III Homme Myélome Protocole thérapeutique Randomisation Thalidomide Traitement Hémopathie maligne Immunoglobulinopathie Immunopathologie Lymphoprolifératif syndrome
- Keyword (en)
- Drug combination Chemotherapy High dose Phase III trial Human Myeloma Therapeutic protocol Randomization Thalidomide Treatment Malignant hemopathy Immunoglobulinopathy Immunopathology Lymphoproliferative syndrome
- Keyword (es)
- Asociación medicamentosa Quimioterapia Dosis fuerte Ensayo clínico fase III Hombre Mieloma Protocolo terapéutico Aleatorización Talidomida Tratamiento Hemopatía maligna Inmunoglobulinopatía Inmunopatología Linfoproliferativo síndrome
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 15236237
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s00277-003-0685-2 
https://dx.doi.org/10.1007/s00277-003-0685-2
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00277-003-0685-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:174:\"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Annals of hematology (Print)\";s:9:\"\u0000*\u0000stitle\";s:21:\"Ann. hematol. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"82\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:3:\"654\";s:8:\"\u0000*\u0000epage\";s:3:\"659\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0939-5555\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"GOLDSCHMIDT\";s:10:\"\u0000*\u0000aufirst\";s:1:\"H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:12:\"SONNEVELD, P\";i:1;s:10:\"HOELZER, D\";i:2;s:8:\"HO, A. D\";i:3;s:14:\"LOKHORST, H. M\";i:4;s:12:\"CREMER, F. W\";i:5;s:15:\"VAN DER HOLT, B\";i:6;s:11:\"WESTVEER, P\";i:7;s:14:\"BREITKREUTZ, I\";i:8;s:9:\"BENNER, A\";i:9;s:13:\"GLASMACHER, A\";i:10;s:21:\"SCHMIDT-WOLF, I. G. D\";i:11;s:9:\"MARTIN, H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:174:\"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00277-003-0685-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:174:\"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Annals of hematology (Print)\";s:9:\"\u0000*\u0000stitle\";s:21:\"Ann. hematol. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"82\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:3:\"654\";s:8:\"\u0000*\u0000epage\";s:3:\"659\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0939-5555\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"GOLDSCHMIDT\";s:10:\"\u0000*\u0000aufirst\";s:1:\"H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:12:\"SONNEVELD, P\";i:1;s:10:\"HOELZER, D\";i:2;s:8:\"HO, A. D\";i:3;s:14:\"LOKHORST, H. M\";i:4;s:12:\"CREMER, F. W\";i:5;s:15:\"VAN DER HOLT, B\";i:6;s:11:\"WESTVEER, P\";i:7;s:14:\"BREITKREUTZ, I\";i:8;s:9:\"BENNER, A\";i:9;s:13:\"GLASMACHER, A\";i:10;s:21:\"SCHMIDT-WOLF, I. G. D\";i:11;s:9:\"MARTIN, H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:174:\"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00277-003-0685-2\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00277-003-0685-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:174:\"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Annals of hematology (Print)\";s:9:\"\u0000*\u0000stitle\";s:21:\"Ann. hematol. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"82\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:3:\"654\";s:8:\"\u0000*\u0000epage\";s:3:\"659\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0939-5555\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"GOLDSCHMIDT\";s:10:\"\u0000*\u0000aufirst\";s:1:\"H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:12:\"SONNEVELD, P\";i:1;s:10:\"HOELZER, D\";i:2;s:8:\"HO, A. D\";i:3;s:14:\"LOKHORST, H. M\";i:4;s:12:\"CREMER, F. W\";i:5;s:15:\"VAN DER HOLT, B\";i:6;s:11:\"WESTVEER, P\";i:7;s:14:\"BREITKREUTZ, I\";i:8;s:9:\"BENNER, A\";i:9;s:13:\"GLASMACHER, A\";i:10;s:21:\"SCHMIDT-WOLF, I. G. D\";i:11;s:9:\"MARTIN, H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:174:\"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00277-003-0685-2\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:174:\"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Annals of hematology (Print)\";s:9:\"\u0000*\u0000stitle\";s:21:\"Ann. hematol. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"82\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:3:\"654\";s:8:\"\u0000*\u0000epage\";s:3:\"659\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0939-5555\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"GOLDSCHMIDT\";s:10:\"\u0000*\u0000aufirst\";s:1:\"H\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:12:\"SONNEVELD, P\";i:1;s:10:\"HOELZER, D\";i:2;s:8:\"HO, A. D\";i:3;s:14:\"LOKHORST, H. M\";i:4;s:12:\"CREMER, F. W\";i:5;s:15:\"VAN DER HOLT, B\";i:6;s:11:\"WESTVEER, P\";i:7;s:14:\"BREITKREUTZ, I\";i:8;s:9:\"BENNER, A\";i:9;s:13:\"GLASMACHER, A\";i:10;s:21:\"SCHMIDT-WOLF, I. G. D\";i:11;s:9:\"MARTIN, H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:174:\"Joint HOVON-50\/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
